Health threats accelerate as medical countermeasures remain early

Summary

New findings suggest amyloid beta may trigger Alzheimer’s earlier than visible plaque buildup by disrupting tau, a protein critical to neuron function. The work reframes plaques as a downstream hallmark rather than the initiating cause.

Why it matters

It could redirect Alzheimer’s R&D and diagnosis toward earlier, more actionable mechanisms instead of late-stage plaque removal.

Summary

Two early recipients of a stem cell based treatment for a severe autoimmune disease affecting the spinal cord and optic nerve have remained free of disease for 15 years. The long follow up suggests the therapy can produce durable remission in cases that historically relapse and accumulate disability.

Why it matters

If durability holds at scale, this approach could move a devastating autoimmune neurologic disease from chronic management toward functional cure for a subset of patients.

Summary

Kardigan’s stock rose 27% on its first day of trading after raising $400 million in an IPO focused on heart-health biotech. The debut indicates strong investor demand for late-stage or differentiated cardiovascular pipelines despite a selective capital market.

Why it matters

A successful, large biotech IPO can unlock follow-on financing across the sector and change which programs get funded next.

Summary

A new study of nursing home residents found that people who received at least one dose of a shingles vaccine were 24% less likely to develop dementia than those who were not vaccinated.

Why it matters

Even a modest, scalable dementia risk reduction tied to an existing vaccine could shift adult immunization priorities and coverage decisions.